Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.210 EUR
31.51 M EUR
4.10 B EUR
194.18 M
About Incyte Corporation
Sector
Industry
CEO
William J. Meury
Website
Headquarters
Wilmington
Founded
1991
ISIN
US45337C1027
FIGI
BBG003899MC4
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where ICY is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TRADEGATE exchange Incyte Corporation stocks are traded under the ticker ICY.
We've gathered analysts' opinions on Incyte Corporation future price: according to them, ICY price has a max estimate of 112.02 EUR and a min estimate of 60.79 EUR. Watch ICY chart and read a more detailed Incyte Corporation stock forecast: see what analysts think of Incyte Corporation and suggest that you do with its stocks.
Yes, you can track Incyte Corporation financials in yearly and quarterly reports right on TradingView.
Incyte Corporation is going to release the next earnings report on Feb 18, 2026. Keep track of upcoming events with our Earnings Calendar.
ICY earnings for the last quarter are 1.93 EUR per share, whereas the estimation was 1.37 EUR resulting in a 40.71% surprise. The estimated earnings for the next quarter are 1.68 EUR per share. See more details about Incyte Corporation earnings.
Incyte Corporation revenue for the last quarter amounts to 1.16 B EUR, despite the estimated figure of 1.07 B EUR. In the next quarter, revenue is expected to reach 1.16 B EUR.
ICY net income for the last quarter is 361.47 M EUR, while the quarter before that showed 343.81 M EUR of net income which accounts for 5.14% change. Track more Incyte Corporation financial stats to get the full picture.
No, ICY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2025, the company has 2.62 K employees. See our rating of the largest employees — is Incyte Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Incyte Corporation EBITDA is 1.15 B EUR, and current EBITDA margin is 3.99%. See more stats in Incyte Corporation financial statements.
Like other stocks, ICY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Incyte Corporation stock right from TradingView charts — choose your broker and connect to your account.